AXSM (Axsome Therapeutics) Selling, General, & Admin. Expense: $634.8 Mil (TTM As of Mar. 2026)


AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $249.19
GF Value $223.61
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Selling, General, & Admin. Expense?

Axsome Therapeutics AXSM -0.23% 52 Selling, General, & Admin. Expense is $634.8 Mil as of Mar. 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $223.61 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Axsome Therapeutics's selling, general, & admin. expense for the three months ended in Mar. 2026 was $185.0 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was $634.8 Mil.


Axsome Therapeutics  (NAS:AXSM) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Axsome Therapeutics Selling, General, & Admin. Expense Related Terms


Axsome Therapeutics Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Axsome Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics Selling, General, & Admin. Expense Chart

Axsome Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.65 159.25 323.12 411.36 570.60

Axsome Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 120.79 130.28 150.24 169.30 185.00

AXSM vs MDGL, IONS, BMRN: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Axsome Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Selling, General, & Admin. Expense falls into.


AXSM
52GF Score
Axsome Therapeutics Inc AXSM
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $634.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $634.8 Mil mean?
Axsome Therapeutics (AXSM) has a Selling, General, & Admin. Expense of $634.8 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Axsome Therapeutics and its competitors.
Is Axsome Therapeutics' Selling, General, & Admin. Expense too high?
Axsome Therapeutics' current Selling, General, & Admin. Expense is $634.8 Mil. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Selling, General, & Admin. Expense compare to MDGL and IONS?
Axsome Therapeutics' Selling, General, & Admin. Expense of $634.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current Selling, General, & Admin. Expense is $634.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Modestly Overvalued. The stock's GF Value™ is $223.61, compared to a current price of $249.19 — trading 11.4% above its estimated fair value. The current Selling, General, & Admin. Expense is $634.8 Mil. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Selling, General, & Admin. Expense is $634.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $249.19 is trading 11.4% above its estimated GF Value™ of $223.61. GuruFocus considers Axsome Therapeutics to be Modestly Overvalued.

Key valuation signals for AXSM:

  • Selling, General, & Admin. Expense: $634.8 Mil
  • GF Value™: $223.61 vs. price of $249.19 (11.4% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$249.19
Price
$223.61
GF Value